News
05.07.21

Eric Garner Named OSRX Chief Commercial Officer

Rapid climb up executive ranks lands Garner at helm of all sales and marketing efforts for ophthalmic compounder. Since joining pharmaceutical startup OSRX® in March 2019 as director of marketing, Eric Garner has quickly ascended the corporate ladder.
05.03.21

Compounded Drugs Improve Compliance, Affordability

By R. Luke Rebenitsch, MD, and Michael C. Stiles, MD — How these medications can help with cataract, refractive and glaucoma patients.
03.01.21

The Switch to Compounded Post-Op Drops … A Godsend

By Gary Wörtz, MD — Four years ago, I saw a potential better solution on the horizon for my cataract and LASIK patients. Given the staff time, energy, costs to my patients and generalized frustrations involved in getting patients their prescription post-operative eye drops, I was primed to make a change.
02.12.21

I See OSRX as the Future of Compounded Ophthalmics

By Steven D. Vold, MD — Convenience, affordability, effectiveness, and simplicity have sold me on compounded drops from OSRX®. I prescribe the fixed combination of Prednisolone, Gatifloxacin and Bromfenac (OMNI by OSRX®) for my refractive corneal laser procedures, including LASIK, PRK and SMILE, as well as my cataract and minimally invasive glaucoma procedures.
02.03.21

Top 10 Reasons Surgeons Prescribe Compounded Post-Op Drops

Since Letterman and his lists are hanging out somewhere in Montana these days, we turned to surgeons across America to give us their reasons for prescribing compounded OMNI drops from OSRX®.
12.15.20

OSRX Compounded Drops Bring Simplicity and Affordability to Eye Care Management

By Steven R. Sarkisian, Jr., MD — OMNI combination drops from OSRX have radically changed my approach to the management of glaucoma as well as post-op cataract care. In my experience it is rare to have something that shifts my practice patterns this significantly.
08.31.20

"State of Therapeutics" on CRST: The Podcast

Listen as Damien F. Goldberg, MD; Denise M. Visco, MD; and Eric Rosenberg, DO, MScEng, read highlights of the July issue of CRST, including the evolution of steroid use in cataract surgery, effective pre- and postoperative drug regimens, and the evolution of 3D visualization platforms.
07.22.20

Simplifying Routines Benefits Patients and the Practice

By Shachar Tauber, MD — In late 2018, the surgeons at Mercy Clinic made a commitment to wholesale changes in our perioperative drop regimen for anterior segment surgery, including cataract, cornea, and laser refractive surgery procedures.
07.21.20

Simplified Regimens, Extended Delivery Options Among Recent Advances in Steroid Delivery for Cataract Surgery

By Damien F. Goldberg, MD — Steroid medications are an integral part of how we care for patients after cataract surgery. I still recall the drop packs my attendings used to give our cataract surgical patients when I started residency.
07.20.20

Compounded Meds Are the Way to Go

By Gary Wörtz, MD — In my opinion, the biggest factor in determining the best pre- and postoperative medication regimen for cataract surgery is simplicity. Faced with multiple medications in different bottles requiring different administration schedules, patients can become confused.
06.12.20

Mail-Order Pharmacies Deliver Peace of Mind During COVID

OSRX ships post-op drops directly to your practice or patients at no added cost, allowing at-risk patients to avoid unnecessary visits to the pharmacy before and after surgery.
06.01.20

Improving Patient Compliance With Compounded Glaucoma Medications

Glaucoma Physician spoke with Steven R. Sarkisian Jr., MD, about how using compounded medications can benefit both patients and providers.
05.12.20

OSRX Launches Online Prescriber Portal

OSRX, the 503A compounding pharmacy affiliate of Southern California biotech Ocular Science®, today introduced an online portal designed to streamline and simplify the prescribing process. The OSRX Prescriber Portal, at osrxpharmaceuticals.com, is a simplified, secure process for submitting, tracking and managing patient scripts.
05.06.20

Drug options proliferate for cataract surgery patients

Dr. Goldberg previously preferred brand-name drug products, but as prices increased sharply over the last 10 years, his practice started to look for alternative solutions, such as compounding. He has become a regular user of a compounded combination of topical antibiotic, steroid, and NSAID (prednisolone/gatifloxacin/bromfenac, OMNI by OSRX).
03.25.20

Compounded drops save time, money

By Gary Wörtz, MD — In my opinion, compounded drops are the closest thing we have seen to the holy grail of postop pharmaceuticals in my career. Not only do compounded drops save patients money, the quality and convenience compared with both brand-name and generic formulations have piqued the interest of both providers and patients.
03.11.20

Why I Prescribe OMNI Combo Drops

Dr. Steven R. Sarkisian, Jr., is the founder and CEO of Oklahoma Eye Surgeons, PLLC, as well as the former director of the glaucoma fellowship at the Dean McGee Eye Institute and clinical professor of Ophthalmology at the University of Oklahoma.
01.15.20

As Profits Rise, Ocular Science Promotes From Within

Ocular Science, which produces and markets ophthalmic formulations for post-op cataract and LASIK procedures, glaucoma management, myopia control and dry eye disease, has promoted Eric Garner to Vice President of Marketing.
01.07.20

Ocular Science Taps Ophthalmology Medical Device Pro to Lead U.S. Sales

Ocular Science®, which produces and markets ophthalmic formulations for post-op cataract and LASIK procedures, glaucoma management, myopia control and dry eye disease, has named Greg Anderson as its vice president of sales.
11.01.19

Simplify Drop Use

It is agreed that controlling inflammation and managing infection risk, via steroids and NSAIDS and antibiotics, respectively, are of monumental importance following cataract surgery.
05.25.19

Ocular Science Launches Two Affiliates to Focus on Compounding and Biologic Sectors

Ocular Science launches two affiliates to focus on compounding and biologic sectors of ophthalmic market.
05.20.19

ASCRS FDA Committee Member Speaks on Access to Compounded Drugs

ASCRS FDA committee member Damien Goldberg, MD, urges FDA to allow access to compounded drugs from traditional compounders without a patient-specific prescription.